Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).

Industry: Pharmaceutical Preparations Peers: Capricor Therapeutics Inc Celcuity Inc PARDES BIOSCIENCES, INC. Icosavax, Inc. Matinas BioPharma Holdings Inc Ovid Therapeutics Inc Precision BioSciences Inc Tenaya Therapeutics Inc Werewolf Therapeutics Inc